Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2Phase 2 2Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 6Pain 3Burns 2Breakthrough Pain 2Anemia, Sickle Cell 2Agnosia 2Pain, Postoperative 1Pain, Intractable 1Lung Neoplasms 1Intrathecal Dexmedetomidine 1Dyspnea, Paroxysmal 1Colonic Neoplasms 1Cancer Pain 1Breast Neoplasms 1Bone Metastases 1

Interventions

Fentanyl 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Breakthrough Pain × Fentanyl × Clear all
NCT03809455 2020-04-22

FARADI

UNICANCER

Phase 2 Withdrawn

Breakthrough Pain

NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡